Statin use and risk of nonmelanoma skin cancer: a nationwide study in Denmark

Br J Cancer. 2015 Jan 6;112(1):153-6. doi: 10.1038/bjc.2014.527. Epub 2014 Oct 7.


Background: Evidence is conflicting regarding statin use and risk of basal cell (BCC) and squamous cell skin cancer (SCC).

Methods: Using Danish nationwide registries, we identified all patients with incident BCC/SCC during 2005-2009 and matched them to population controls. We computed odds ratios (ORs) for BCC and SCC associated with statin use.

Results: We identified 38,484 cases of BCC and 3724 cases of SCC. Statin ever use was associated with ORs of 1.09 (CI: 1.06-1.13) for BCC and 1.01 (CI: 0.91-1.11) for SCC.

Conclusions: Statin use was not associated with risk of SCC. Residual confounding plausibly explains the marginally increased risk of BCC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Case-Control Studies
  • Denmark / epidemiology
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
  • Male
  • Middle Aged
  • Risk
  • Skin Neoplasms / epidemiology*


  • Hydroxymethylglutaryl-CoA Reductase Inhibitors